FDA Approves Mydcombi (tropicamide and phenylephrine hydrochloride) Ophthalmic Spray forInducing Mydriasis

U.S.-Death-Rate-Declined-in-2022-COVID-Deaths-Fell-by-Almost-Half
U.S. Death Rate Declined in 2022, COVID Deaths Fell by Almost Half
May 4, 2023
FDA Approves Elfabrio (pegunigalsidase alfa-iwxj) for the Treatment of Adult Patients with FabryDisease
May 10, 2023
U.S.-Death-Rate-Declined-in-2022-COVID-Deaths-Fell-by-Almost-Half
U.S. Death Rate Declined in 2022, COVID Deaths Fell by Almost Half
May 4, 2023
FDA Approves Elfabrio (pegunigalsidase alfa-iwxj) for the Treatment of Adult Patients with FabryDisease
May 10, 2023

May 08, 2023 - Eyenovia, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved Mydcombi (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5% for inducing mydriasis for diagnostic procedures and in conditions where short term pupil dilation is desired. This represents the first approved fixed dose combination of tropicamide and phenylephrine in the United States and also the first product using Eyenovia’s proprietary Optejet device to be approved by any regulatory authority.

Mydcombi is designed to improve the efficiency of the estimated 106 million office-based comprehensive eye exams performed every year in the United States, as well as the estimated 4 million pharmacologic mydriasis applications for cataract surgery. The product is contraindicated and should not be used in patients with known hypersensitivity to any component of the formulation.

Read more…